[go: up one dir, main page]

MX2011011881A - Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes. - Google Patents

Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.

Info

Publication number
MX2011011881A
MX2011011881A MX2011011881A MX2011011881A MX2011011881A MX 2011011881 A MX2011011881 A MX 2011011881A MX 2011011881 A MX2011011881 A MX 2011011881A MX 2011011881 A MX2011011881 A MX 2011011881A MX 2011011881 A MX2011011881 A MX 2011011881A
Authority
MX
Mexico
Prior art keywords
diabetes
derivatives
prediabetes
prepare
delphinidin
Prior art date
Application number
MX2011011881A
Other languages
Spanish (es)
Inventor
Agustin Lugo Radillo
Original Assignee
Agustin Lugo Radillo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agustin Lugo Radillo filed Critical Agustin Lugo Radillo
Priority to MX2011011881A priority Critical patent/MX2011011881A/en
Priority to PCT/MX2012/000102 priority patent/WO2013058644A1/en
Publication of MX2011011881A publication Critical patent/MX2011011881A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de la delfinidina y sus derivados para preparar un medicamento para el tratamiento de la prediabetes y diabetes. Su efecto consiste en la reducción de la concentración plasmática de glucosa posterior a su administración. Dicho medicamento destinado al tratamiento de la prediabetes y diabetes puede contener la delfinidina o alguno de sus derivados de manera individual o en múltiples combinaciones. Así mismo, dicho medicamento puede contener en combinación otros productos farmaceúticos. De igual manera, puede utilizarse cualquier vía de administración. Dicho medicamento que contenga delfinidina o alguno de sus derivados y esté destinado al tratamamiento de prediabetes y diabetes puede administrarse a cualquier organismo eucariota, incluyendo el humano.Use of delfinidine and its derivatives to prepare a medication for the treatment of prediabetes and diabetes. Its effect consists in the reduction of the plasma glucose concentration after its administration. Said medicament for the treatment of prediabetes and diabetes may contain delfinidine or any of its derivatives individually or in multiple combinations. Likewise, said medication may contain in combination other pharmaceutical products. Similarly, any route of administration can be used. Said medicine that contains delfinidine or any of its derivatives and is intended for the treatment of prediabetes and diabetes can be administered to any eukaryotic organism, including humans.

MX2011011881A 2011-10-17 2011-10-17 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes. MX2011011881A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2011011881A MX2011011881A (en) 2011-10-17 2011-10-17 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.
PCT/MX2012/000102 WO2013058644A1 (en) 2011-10-17 2012-10-15 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2011011881A MX2011011881A (en) 2011-10-17 2011-10-17 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.

Publications (1)

Publication Number Publication Date
MX2011011881A true MX2011011881A (en) 2013-04-17

Family

ID=48141151

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011881A MX2011011881A (en) 2011-10-17 2011-10-17 Use of delphinidin and the derivatives thereof to prepare a drug for treating prediabetes and diabetes.

Country Status (2)

Country Link
MX (1) MX2011011881A (en)
WO (1) WO2013058644A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060234957A1 (en) * 2003-03-03 2006-10-19 Takanori Tsuda Adiponectin expression promoter
US7772195B2 (en) * 2004-07-29 2010-08-10 Board Of Trustees Of Michigan State University Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia
US20090176718A1 (en) * 2007-10-31 2009-07-09 David Ribnicky Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome

Also Published As

Publication number Publication date
WO2013058644A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
NI201100194A (en) DERIVATIVES OF HAVE [2, 3 - B] PYRIDINE AS INHIBITORS OF VIRAL REPLICATION
BR112013027119A8 (en) new ligand-drug conjugates (adcs) and their use
PE20142319A1 (en) MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE
MX2015012559A (en) NEW HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS FOR THE TREATMENT OF PARKINSON DISEASES.
HK1221646A1 (en) Use of high dose pridopidine for treating huntington's disease
EA201401028A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING EMAGOGLIFLOZIN AND MEDICINES FOR OBESITY
CL2013003298A1 (en) Use of methotrexate because it is used to prepare a medicine, useful in the treatment of diseases that need treatment with a therapeutic product that produces autoimmunity, administered in a single cycle.
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
BR112012030641A2 (en) methods and compositions for oral pharmaceutical therapy
MX380480B (en) PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN.
BR112015003836A2 (en) drug delivery systems and methods for bladder cancer treatment
AR106364A1 (en) INSULIN DERIVATIVES AND THEIR MEDICAL USES
AR097619A1 (en) USE OF ACETIL-COA CARBOXYLASE INHIBITORS TO TREAT ACNÉ VULGARIS
EA201391689A1 (en) SYSTEM OF DELIVERY MEDICINE
BR112015004110A2 (en) prostate drug delivery systems and methods
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
BR112013027010A2 (en) method of producing substances with supersaturated gas, device for their transdermal delivery, and their uses
CO7101244A2 (en) Substituted phenylimidazopyrazoles and their use
CO6180495A2 (en) FORMULATION OF LIQUID MEDICINAL PRODUCT
BR102012028120B8 (en) USE OF ONE OR MORE INGENOL DERIVATIVES, PHARMACEUTICAL COMPOSITION AND DRUG
AR079000A1 (en) ANTI-BANK THERAPY AIMED AT CANCEROSA MOTHER RESISTANT DRUG CELLS
NI201000181A (en) USE OF DRONEDARONE TO PREPARE A MEDICINAL PRODUCT FOR THE TREATMENT OF PATIENTS WITH ARRHYTHMIA AND WHO HAVE AN INCREASED CREATININE LEVEL DUE TO THE ADMINISTRATION OF DRONEDARONE.
CL2010001577A1 (en) Use of nifurtimox to prepare a useful medicine in the treatment of diseases caused by giardias.
IL217519A (en) Derivatives of tazarotene, pharmaceutical preparations containing them and their use in the preparation of medicines for the treatment of skin diseases
AR086491A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING FEXOFENADINE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal